BERGEN, Norway, May 15, 2019 /PRNewswire/ --
- Two peer reviewed abstracts on Phase II clinical data with
bemcentinib accepted for presentation at ASCO 2019
- Non-Small-Cell Lung Cancer (NSCLC) trial of bemcentinib in
combination with pembrolizumab, data to be presented includes
safety, response rates and overall survival
- Acute Myeloid Leukaemia (AML) trial of bemcentinib in
combination with low dose AraC chemotherapy or decitabine reported
safety and rapid, durable complete response rates
BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical
company developing novel, selective AXL kinase inhibitors for
multiple cancer indications, notes the publication of abstracts
relating to new interim clinical and biomarker data that the
company and its collaborators will present from its extensive Phase
II clinical development programme with bemcentinib at the 2019
annual meeting of the American Society of Clinical Oncology (ASCO)
at McCormick Place in Chicago,
Illinois (31 May - 4 June
2019).
The abstracts have been made available online at
abstracts.asco.org today and details of the presentations are
below.
The posters presented at ASCO will be made available at
www.bergenbio.com in the Investors / Presentations section to
coincide with the following conference sessions:
Sunday 2 June, 8:00 AM –
11:30 AM Central Daylight
Time
A Phase II study of bemcentinib (BGB324), a first-in-class
highly selective AXL inhibitor, with pembrolizumab in patients with
advanced NSCLC: OS for stage I and preliminary stage II
efficacy.
- Enriqueta Felip et
al
- Session: Lung Cancer – Non-Small Cell Metastatic
- Location: Hall A, poster board #421, abstract 9098
Data highlights:
- Phase II clinical trial assessing bemcentinib in combination
with pembrolizumab (KEYTRUDA) in advanced lung cancer patients post
chemotherapy.
- The combination treatment of bemcentinib and pembrolizumab was
overall well-tolerated.
- Promising clinical activity continues to be seen overall,
particularly in patients with AXL positive tumours including those
with weak or no PD-L1 expression.
- Updated results will be reported at the meeting, including the
12-month overall survival for stage 1 and preliminary efficacy of
Stage 2.
Monday 3 June, 8:00 AM –
11:30 AM Central Daylight
Time
First-in class selective AXL inhibitor bemcentinib (BGB324) in
combination with low dose AraC (LDAC) or decitabine exerts
anti-leukaemia activity in AML pts unfit for intensive
chemotherapy: Phase II open-label study.
- Dr Sonja Loges et
al
- Session: Hematologic Malignancies – Leukaemia, Myelodysplastic
Syndromes, and Allotransplant
- Location: Hall A, poster board #418, abstract 7043
Data highlights:
- Bemcentinib in combination with LDAC exerted early onset and
durable responses in patients with both de novo and relapsed AML,
whilst the combination of bemcentinib and decitabine exerted
comparably fewer and later responses in de novo AML.
- Both combinations were generally well-tolerated.
- Updated results will be presented.
Richard Godfrey, Chief
Executive Officer of BerGenBio, commented: "We are encouraged
by the promising data that continues to emerge from our clinical
development programme with bemcentinib in AML and NSCLC. Following
the data that was gathered in January, we have expanded our
clinical programmes in both indications and, together with our
investigators, look forward to providing further important findings
at ASCO.
"Most NSCLC patients in Europe
now receive anti-PD(L)-1 therapies like KEYTRUDA as a first- or
second-line treatment for their advanced disease. Improving
responses to these novel agents, particularly in patients with no
or limited expression of PD-L1, who may not have benefitted from
such therapies, is significant. Similarly, positive responses in a
less fit AML patient population considered to have unfavourable
prognosis after the failure of first-line therapies, or those with
high risk cytogenetics is very encouraging."
About BerGenBio
BerGenBio is a clinical-stage biopharmaceutical company focused
on developing transformative drugs targeting AXL as a potential
cornerstone of therapy for aggressive diseases, including
immune-evasive, therapy resistant cancers. The company's
proprietary lead candidate, bemcentinib, is a potentially
first-in-class selective AXL inhibitor in a broad Phase II oncology
clinical development programme focussed on combination and single
agent therapy in lung cancer and leukaemia. A first-in-class
functional blocking anti-AXL antibody is undergoing Phase I
clinical testing. In parallel, BerGenBio is developing a companion
diagnostic test to identify those patient populations most likely
to benefit from bemcentinib: this is expected to facilitate more
efficient registration trials supporting a precision medicine-based
commercialisation strategy. BerGenBio is based in Bergen, Norway with a subsidiary in
Oxford, UK. The company is listed
on the Oslo Stock Exchange (ticker: BGBIO). For more information,
visit www.bergenbio.com
Forward looking statements
This announcement may contain forward-looking statements, which
as such are not historical facts, but are based upon various
assumptions, many of which are based, in turn, upon further
assumptions. These assumptions are inherently subject to
significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and
other important factors could cause actual events to differ
materially from the expectations expressed or implied in this
announcement by such forward-looking statements.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/bergenbio-asa/r/bergenbio-to-present-new-nsclc-and-aml-clinical-data-and-biomarker-data-from-phase-ii-development-pr,c2815049
Contacts
Richard Godfrey CEO, BerGenBio
ASA
+47-917-86-304
Rune Skeie, CFO, BerGenBio
ASA
rune.skeie@bergenbio.com
+47-917-86-513
International Media and Investor Relations
Mary-Jane Elliott, Chris Welsh, Nicholas
Brown, Carina Jurs, Consilium
Strategic Communications
bergenbio@consilium-comms.com
+44-20-3709-5700
Media Relations in Norway
Jan
Petter Stiff, Crux Advisers
stiff@crux.no
+47-995-13-891